Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

Core Insights - Moderna, Inc. announced data on two investigational influenza candidates to be presented at IDWeek 2025, highlighting advancements in mRNA-based vaccine technology [1] Group 1: Presentation Details - The Late-Breaking Oral Presentation 229 will focus on mRNA-1010, an mRNA-based influenza vaccine [1] - Data indicates that mRNA-1010 is safe and efficacious in adults aged 50 years [1] - The relative vaccine efficacy (rVE) of mRNA-1010 is compared to a licensed standard dose (SD) influenza vaccine [1]